| Open |
S2303 |
Adding Nivolumab to Usual Treatment for People with Advanced Stomach or Esophageal Cancer |
5/6/2024 |
|
49% |
|
|
| Open |
S1900K |
Targeted Treatment for Advanced NSCLC that has a MET Exon 14 Skipping Gene Change |
12/18/2023 |
|
52% |
|
|
| Open |
S2213 |
A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab… |
12/1/2023 |
|
35% |
|
|
| Open |
S2206 |
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor… |
10/30/2023 |
|
42% |
|
|
| Open |
S2210 |
Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency |
8/14/2023 |
|
14% |
|
|
| Open |
S2212 |
SCARLET |
7/21/2023 |
|
66% |
|
|
| Open |
S2207 |
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment |
6/30/2023 |
|
23% |
|
|
| Open |
S2209 |
VRd-Lite versus DRd followedby Len+/-Dara |
5/30/2023 |
|
28% |
|
|
| Open |
S1900G |
Comparing Combinations of Targeted Drugs for Advanced NSCLC that has EGFR and MET Gene Changes |
4/3/2023 |
|
64% |
|
|
| Open |
S2205 |
ICE COMPRESS |
3/16/2023 |
|
84% |
|
|
| Closed |
S2302 |
PRAGMATICA - LUNG |
3/6/2023 |
12/20/2024 |
100% |
|
|
| Open |
EAY191-S3 |
ComboMATCH S3 |
3/6/2023 |
|
100% |
|
|
| Open |
S2114 |
Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL |
2/23/2023 |
|
61% |
|
|
| Closed |
S2010 |
ASPEN |
1/17/2023 |
1/15/2025 |
100% |
|
|
| Open |
S2101 |
BiCaZO - iMATCH pilot |
10/14/2022 |
|
49% |
|
|
| Closed |
S2200 |
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2 |
9/19/2022 |
1/17/2026 |
18% |
|
|
| Closed |
S2108CD |
Genomic tumor board study |
8/22/2022 |
|
100% |
|
|
| Closed |
S1900F |
A Randomized Phase II Study of Carboplatin and Pemetrexed With Or Without Selpercatinib In Patients With Non-Squamous RET Positive Stage IV NSCLC and Progression of Disease On Prior RET Directed Therapy |
7/25/2022 |
6/27/2023 |
0% |
|
|
| Closed |
S2107 |
Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable… |
6/6/2022 |
10/1/2024 |
100% |
|
|
| Closed |
S1800D |
LUNGMAP S1800D: Non-match Sub-Study |
2/15/2022 |
3/10/2023 |
17% |
|
|
